Clinical Trial

X-linked Hypophosphatemia Disease Monitoring Program

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
Protocol Amendment History 75 amendments
This ClinicalTrials.gov record has been amended 75 times since 2018-08-28; most recent amendment 2026-05-20.
Status change: Recruiting → Active, Not Recruiting 2022-12-07
Status change: Active, Not Recruiting → Recruiting 2020-06-12
Status change: Recruiting → Active, Not Recruiting 2020-04-02
Trial Details
NCT Number NCT03651505
Lead Sponsor Ultragenyx Pharmaceutical Inc
Collaborators: Kyowa Kirin Co., Ltd.
Conditions X-linked Hypophosphatemia, Hypophosphatemic Rickets
Enrollment 782 participants
Start Date 2018-07-16
Primary Completion 2032-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22